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Abstract: Background: Biliary complications are a leading source of
surgical morbidity following orthotopic liver transplantation (OLT).
Methods: We examined how prophylactic internal biliary stent
placement during OLT aﬀected post-transplant morbidity and mortality
in a single-center retrospective cohort study of 513 recipients (2006–
2012). Recipient and donor covariates were collected. Biliary
complications included major and minor anastomotic leaks, strictures, or
stenoses. Multivariate regression models were created to estimate how
operative biliary stents aﬀected outcomes.
Results: About 87.3% (n = 448) of recipients had a duct-to-duct biliary
anastomosis, and 43.1% (n = 221) had biliary stents placed. The biliary
complication rate was <15% at ﬁve yr, and 44.8% (n = 230) overall.
Stenting was not protective from anastomotic biliary complications
(p = 0.06). Stenting was associated with a 74% higher adjusted risk of
needing multiple endoscopic retrograde cholangiographies (ERCs; odds
ratio [OR] 1.74, p = 0.011), and trended toward a lower adjusted risk for
repetitive percutaneous transhepatic cholangiography (PTCs; OR 0.56,
p = 0.063). Stenting had no eﬀect on the cumulative freedom from biliary
complications (p = 0.94). Biliary complications were associated with
mortality (HR 1.86, p = 0.014) and was unaﬀected by stenting
(aHR = 0.72, p = 0.246).
Conclusions: Biliary stenting during OLT does not deter biliary
complications and is associated with higher risk of multiple invasive
biliary interventions, particularly ERCs. Surgeons should evaluate the
utility of biliary stents at OLT within this context.
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Despite signiﬁcant advances in orthotopic liver
transplantation (OLT) technique, and recipient
and donor selection, complications arising from
the biliary anastomosis are a continued source of
signiﬁcant morbidity and mortality for patients
after transplant. Recent reports identify a signiﬁ-
cant rate of these complications, up to 30–40%
over time (1–5). Biliary complications signiﬁcantly
increase morbidity for patients and are costly for
hospitals (6). Several risk factors have been associ-
ated with a higher risk of biliary complications
including the use of partial liver grafts, cold
and warm ischemic time, arterial complications,
donor age, weight, graft steatosis, and recipient
smoking status (3, 5–8). Many transplant surgeons
have looked to stenting the biliary anastomosis
using internal silastic pediatric feeding tubes,
transcystic tubes, or T-tubes to preclude these com-
plications.
T-tubes have not demonstrated a clear beneﬁt in
prospective trials, but other biliary stenting tech-
niques have shown promise in retrospective studies
(4, 5, 9). The use of operatively placed internal bili-
ary stents remains controversial, underscoring the
wide variation in the surgical management of the
bile duct in liver transplantation (10). It is further
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unknown whether intra-operative internal biliary
stents themselves contribute to any post-OLT
morbidity. Depending on the type of stent used,
various complications may occur. Cholangitis due
to stent obstruction, intrahepatic stent migration,
hemobilia, visceral injury, intestinal ﬁstula, or
biliary peritonitis after stent removal have been
reported (9, 11–20). These complications may
require additional invasive treatments. Endoscopic
retrograde cholangiography (ERC) stents and per-
cutaneous transhepatic cholangiographic (PTC)
catheterization are the treatments of choice for
anastomotic biliary leaks and strictures after OLT,
but are costly, invasive, and carry their own risks.
It is unknown how the practice of intra-operative
internal biliary stenting aﬀects the need for these
interventions after OLT.
In this study, we retrospectively reviewed our
experience with intra-operative internal biliary
stent placement during OLT, subsequent biliary
complications, and utilization rates of invasive bili-
ary interventions, including ERC, PTC, and eso-
phago-gastric-duodenoscopy (upper endoscopy)
(EGD). We further evaluated the eﬀects of stenting
practices on post-OLT survival to better inform
surgeons about the risks and beneﬁts of this prac-
tice and improve surgical decision-making.
Methods
A total of 537 adult patients were retrospectively
reviewed at our institution from January 1, 2006,
to December 31, 2012. Recipient and donor demo-
graphics, transplant procedural factors, and post-
transplant events were collected from patient
records. Recipient factors included age, sex, race/
ethnicity, primary diagnosis, Model for End-Stage
Liver Disease (MELD) score, cardiovascular dis-
ease, hypertension, diabetes, and smoking status
(active, former, lifetime non-smoker). Donor fac-
tors included age, sex, race/ethnicity, and donor
type (brain death, donation after cardiac death, liv-
ing donor). Procedural factors included type of
graft (whole organ or split graft), primary trans-
plant vs. retransplant, use of an internal biliary
stent, cold ischemia time, warm ischemia time, and
type of anastomosis.
Surgical management and immunosuppression
At transplant, the biliary anastomosis was con-
structed at the discretion of the attending surgeon
based on anatomy and primary disease process
and was either a choledochodochostomy or bili-
ary–enteric anastomosis using a Roux-en-Y conﬁg-
uration. All biliary anastomoses were performed
using 5–0 or 6–0 polydioxanone suture (PDS) in
either a running or interrupted fashion. The donor
and recipient bile ducts were also shortened and
spatulated at the surgeon’s discretion. The use of
an internal biliary stent was also placed at the dis-
cretion of the surgeon performing the procedure
and consisted of placing a silastic 5F or 8F pediat-
ric feeding tube with customized side holes placed
into the biliary tree and positioned with one end
through the ampulla and the other end above
the level of the anastomosis. Post-OLT immuno-
suppression included triple immunosuppressive
therapy, which included a calcineurin inhibitor,
mycophenylate mofetil, as well as steroids. Patients
with renal dysfunction underwent induction immu-
nosuppression with anti-CD25 chimeric monoclo-
nal antibody therapy (basiliximab) with delayed
initiation of calcineurin inhibitors. Patients with
stents were veriﬁed to have passed their stents with
use of plain abdominal radiography at three wk.
Patients who failed to pass their stents spontane-
ously underwent elective EGD for stent removal.
Defining biliary complications
Biliary complications were identiﬁed by review of
patient records and were diagnosed clinically (pres-
ence of biliary ascites, bile in drain, bilious wound
drainage) or by imaging (ERC or PTC). Non-anas-
tomotic or intrahepatic strictures were excluded
from this study (n = 24), which were identiﬁed
based on appearance on cholangiogram. The deci-
sion to perform either ERC or PTC was based on
any suspicion of a biliary complication based on
clinical judgment and laboratory studies. All bili-
ary complications that occurred following liver
transplantation were included in the analysis until
the end of follow-up. Biliary leaks were deﬁned as
major or minor, as determined by clinical interpre-
tation of cholangiogram studies by surgeons, radi-
ologists, and gastroenterologists. The incidence of
an invasive biliary intervention including ERC,
PTC, or EGD was also recorded for each patient,
and counts of each procedure per patient were
recorded. Notably, our center practice utilizes
ERC as a ﬁrst-line intervention for suspected bili-
ary complications in patients with choledochocho-
ledochostomy. PTC was reserved for those patients
with suspected leaks or strictures at a biliary–
enteric anastomosis, or with any severe leak to
facilitate internal and external biliary drainage.
Statistical analysis
Our primary exposure variable was the use of
intra-operative biliary stents at OLT. We classiﬁed
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and calculated diﬀerences in the rates of speciﬁc
biliary complications using univariate statistics.
The Kaplan–Meier method was used to estimate
biliary complication event rates over time. To
determine the eﬀect of stenting on biliary compli-
cations, we used a similar multivariate Cox model
approach to determine the time to ﬁrst biliary com-
plication as we have previously described (5). The
adjustment covariates included the recipient,
donor, and transplant procedural factors, and year
of transplant. The eﬀect of hepatic artery thrombo-
sis was also included in the model as a time-depen-
dent covariate. Each model was censored at death
or at the end of follow-up. Covariates were
included in the model based on a signiﬁcant eﬀect
on univariate analysis or on potential biological
plausibility.
We further designed models to determine
whether stenting was associated with repetitive
invasive biliary intervention. We used univariate
and multivariate ordinal logistic regression analy-
ses to identify whether the biliary stenting aﬀected
the occurrence of multiple ERCs, PTC interroga-
tions, and EGDs. Ordinal logistic regression mea-
sures the eﬀect of an exposure covariate on the rate
of transition in an ordered response variable; that
is, the occurrence of a third ERC happens only
after a second ERC. This model structure is parsi-
monious and decreases any bias that may arise
from using a count data model structure, which
assumes outcomes as a part of a stochastic process.
To evaluate longer-term outcomes, we used multi-
variate Cox regression methods and the Nelson–
Aalen hazard estimator to evaluate diﬀerences in
the rate of death-censored freedom from biliary
complications based on stent utilization. These
models were adjusted for recipient and donor
demographics, clinical factors including diagnosis,
recipient comorbidities, laboratory MELD at
transplant, and year of transplant. We additionally
designed multivariate Cox proportional hazards
regression models to determine whether biliary
complications had any eﬀect on survival after liver
transplant, and whether this was modiﬁed by the
use of a stent in the odds ratio (OR). These models
were censored for occurrence of retransplant. Risk
adjustment covariates included recipient and
donor demographics, clinical factors including
diagnosis, recipient comorbidities, laboratory
MELD at transplant, year, cold ischemic time, and
warm ischemic time.
The study was approved by the local Institu-
tional Review Board. STATA version 10.0 (Col-
lege Station, TX, USA) was used to complete all
statistical analyses. Statistical signiﬁcance was
deﬁned at a p value of <0.05.
Results
After exclusions for the development of intrahe-
patic or non-anastomotic strictures (n = 24), 513
patients of the study cohort were included in the
ﬁnal analysis. Two hundred and twenty-one
patients (43%) were stented internally in the oper-
ating room at the time of liver transplant. By year,
there was a signiﬁcantly greater utilization of
stents with time, ranging from 19.8% of trans-
plants in 2006 to 63.8% in 2012. The clinical char-
acteristics of the study population are shown in
Table 1. There were some recipient-, donor-, and
operation-speciﬁc diﬀerences between the stented
and non-stented population on univariate analysis.
Female patients (n = 248) made up 48% of the
study cohort. The majority of patients in each
racial/ethnic group were not stented. Female
patients had almost a threefold higher odds of not
being stented than being stented (OR 2.70,
p < 0.001). Hepatocellular cancer recipients were
overrepresented in the stent group (stented 32.1%
vs. non-stented 26.7%), likely owing to the con-
comitant era eﬀects in stent usage and shift toward
more transplants for this diagnosis. MELD scores
at transplant were similarly distributed between
stent and non-stent groups. Seventy-one percent-
age of retransplants were not stented. Greater than
90% of patients in each group received liver grafts
from brain-dead donors. The distribution of donor
causes of death was similar between stent and non-
stent groups, but death from cerebrovascular
causes was almost twofold higher in the stent pop-
ulation. From a technical standpoint, warm ische-
mia time was lower in the stent group, likely
related to secular changes in operative technique
over time. The rates of choledochodochostomy
were similar between stent and non-stent groups
(48% vs. 52%, respectively), but over 90% of
patients who had a biliary–enteric anastomosis
were not stented.
Within the ﬁrst ﬁve yr after transplant, <15% of
all patients had a biliary diagnosed complication.
However, biliary complications did aﬀect 44.3% of
patients in long-term follow-up (Fig. 1). By era,
the complication rate declined, with 31% of recipi-
ents presenting with biliary complications in 2012
at the end of follow-up. Of those who had a biliary
complication (n = 230), 46.1% had anastomotic
leaks (n = 109), but only 25% of those were classi-
ﬁed as major leaks (n = 27, 5% of total popula-
tion). By stent group, a greater proportion of
patients with bile leaks were not stented, but stent-
ed patients had a higher rate of biliary strictures
and leaks with a subsequent stricture. Overall,
there was no signiﬁcant association between rate of
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biliary complication and stent usage on univariate
analysis (p = 0.06).
Fig. 2 demonstrates the distribution of invasive
procedures utilized for biliary complications based
on stent usage. Across the entire population, 2062
interventions were performed in the cohort.
Patients averaged 4.1  8.1 invasive procedures in
total. There were signiﬁcantly more procedures
performed in patients who were not stented (non-
stent vs. stent, 1291 vs. 771, p < 0.05), owing to the
signiﬁcantly greater number of PTC placement and
exchanges in patients who were not stented. There
was no diﬀerence in the utilization of ERC for
cause in the stented population (non-stent vs. stent,
339 vs. 358, p = NS). Interestingly, there were
slightly greater number of EGD procedures per-
formed for stent retrieval in the group who were
not stented in the OR, likely owing to the subse-
quent need for an ERC-placed endo-biliary stent
and an obligatory procedure for stent retrieval at a
later point.
The association between the use of an intra-
operative stent and the likelihood of repetitive
biliary intervention is depicted in Fig. 3. Intra-
operative biliary stenting was associated with a
twofold higher odds of requiring multiple ERCs
Table 1. Clinical and demographic differences between 513 liver transplant recipients by intra-operative internal biliary stenting practice
Variable No biliary stent (n = 292) Internal biliary stent (n = 221) p Value
Recipient factors
Age at transplant (yr) 52.3  10.3 52.6  9.7 0.71
Sex (% female) 181 (62) 67 (30.3) <0.001
Race (% group) 0.15
White 240 (82.2) 172 (77.8)
Black 29 (9.9) 26 (11.8)
Asian 10 (3.4) 4 (1.8)
Other 13 (4.5) 19 (8.6)
Median Model for End Stage Liver
Disease score (IQR)
21 (16, 24) 20 (14, 27) 0.41
Primary diagnosis (%) <0.001
Hepatitis B/C (n = 104) 57 (19.5) 47 (20.3)
EtOH cirrhosis (n = 58) 27 (9.3) 31 (14.0)
HCC (n = 149) 78 (26.7) 71 (32.1)
Cholestatic (n = 77) 65 (22.3 12 (5.4)
Cryptogenic (n = 55) 23 (7.8) 32 (11.5)
Fulminant (n = 14) 6 (2.1) 8 (3.6)
Other (n = 37) 22 (7.5) 15 (6.8)
Retransplant (n = 42) 30 (10.3) 12 (5.4)
Comorbidities (%)
Hypertension (n = 159) 93 (31.9) 66 (29.9) 0.63
Diabetes mellitus (n = 136) 83 (28.4) 53 (24.0) 0.26
Coronary artery disease (n = 34) 19 (6.5) 15 (6.8) 0.90
Smoking (%) 0.28
Lifetime non-smoker (n = 253) 150 (51.4) 103 (46.6)
Former smoker (n = 217) 115 (39.4) 102 (46.1)
Active smoker (n = 43) 27 (9.3) 16 (7.3)
Donor factors
Age at donation (yr) 38.3  16.5 39.3  16.2 0.48
Sex (% female) 110 (39.9) 83 (39.0) 0.84
Cause of death (%)
Anoxia (n = 193) 114 (39.0) 79 (35.8) 0.05
Cerebrovascular (n = 68) 28 (9.6) 40 (18.1)
Cardiovascular (n = 25) 17 (5.8) 8 (3.6)
Head trauma (n = 182) 104 (35.6) 78 (35.3)
Living donor (n = 3) 1 (0.34) 2 (0.90)
Other (n = 45) 28 (9.6) 13 (5.9)
Donation after cardiac death (n = 26) 13 (4.5) 13 (5.9) 0.47
Transplant factors
Split graft (%) 11 (3.8) 12 (5.4) 0.36
Cold ischemia time (min) 424.5  139.4 402.2  174.5 0.11
Warm ischemia time (min) 34.3  14.3 30.2  8.1 0.0002
Biliary anastomosis type (%) <0.001
Choledochodochostomy (n = 448) 233 (79.8) 215 (97.3)
Roux-en-Y hepaticojejunostomy (n = 65) 59 (20.2) 6 (2.7)
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Fig. 1. Rates of speciﬁc biliary
complications after orthotopic liver
transplantation (OLT) by intra-
operative biliary stent use, n = 513.
About 43.1% of patients underwent
intra-operative biliary stenting at OLT,
but there was no signiﬁcant diﬀerence
in the distribution or type of biliary
complications identiﬁed post-
operatively based on the stent
utilization. There was a trend toward
more leaks in the non-stented group,
and more strictures in the stented
group, but these were not statistically
signiﬁcant on univariate analysis.
Fig. 2. Total number of biliary interventions after orthotopic liver transplantation (OLT) by intra-operative biliary stent use. A total
of 2062 procedures were performed across the OLT population (n = 513), averaging four invasive biliary procedures per patient.
There were signiﬁcantly more procedures performed in the non-stent group (n = 1291) vs. stent group (n = 771; p < 0.05), which pri-
marily was driven by diﬀerences in the total number of percutaneous transhepatic cholangiography (PTC) procedures performed in
non-stented patients. These diﬀerences were unadjusted for other clinical covariates.
Fig. 3. Likelihood of repetitive
invasive interventions for biliary
complications based on utilization of
an intra-operative biliary stent. The
eﬀect of intra-operative biliary stenting
on utilization of diﬀerent invasive
biliary procedures was evaluated using
unadjusted and adjusted multivariable
ordinal logistic regression models. Even
after adjusting for clinical covariates,
stented patients had nearly twofold
higher odds of multiple endoscopic
retrograde cholangiographies (ERCs).
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(OR 2.11, p < 0.001). After adjusting for clinical
risk factors, there was a 74% higher risk of patients
needing multiple ERCs associated with intra-oper-
ative biliary stenting. However, intra-operative
stenting was associated with a 54% lower odds of
requiring multiple PTC exchanges on unadjusted
analysis (OR 0.46, p = 0.001). The risk-adjusted
model suggested a trend toward lower rates of
repetitive PTCs, but this was not statistically signif-
icant (OR 0.56, p = 0.06). Over time, beyond the
peri-transplant period, stented and non-stented
patients had similar odds of upper endoscopy.
However, in a subgroup analysis, within the ﬁrst
90 d, stented patients had a threefold higher odds
of needing multiple upper endoscopy procedures
(data not shown; OR 3.58, p = 0.01).
Figs. 4 and 5 demonstrate the long-term out-
comes of patients in the study cohort. After the
development of biliary complications, there was no
signiﬁcant diﬀerence in the rate of freedom from
having an indwelling biliary stent or needing addi-
tional biliary therapy between those stented at
OLT vs. those who were not on unadjusted and
adjusted analysis (p = 0.94). Notably, the presence
of an anastomotic biliary complication was signiﬁ-
cantly associated with increased adjusted risk of
mortality after OLT (HR = 1.87, p = 0.01; Fig. 5),
and intra-operative internal stenting was not asso-
ciated with any eﬀect on survival (HR 0.71,
p = 0.246).
Discussion
Anastomotic biliary complications are the Achilles’
heel of the liver transplant operation. Rates of bili-
ary complications after liver transplant vary across
the literature (1, 2, 21) and are reported to aﬀect as
many as 10–40% patients after transplant (5, 6).
Several authors have described the incidence, treat-
ment, and management of biliary complications
after deceased donor and living donor liver trans-
plant (1, 2, 4–6, 21). A salient patient-centered out-
come in liver transplantation is the number and
invasiveness of procedures used to manage biliary
complications. While the management of these
complications has been driven by non-operative
endoscopic and percutaneous advances, these pro-
cedures are inconvenient, uncomfortable, and
carry quantiﬁable risks of major complications
(12). While the use of T-tubes has been studied, it
is unknown whether intra-operative internal biliary
stenting aﬀects the utilization of these procedures,
which we measured by the number and the need
for repetitive invasive interventions. Stenting the
biliary tree using internal feeding tubes at trans-
plant, in this cohort, did not reduce the risk of bili-
ary complications or mortality and was associated
with greater morbidity. Stented patients had higher
adjusted risk of needing multiple ERCs over time
and EGDs in the ﬁrst 90 d, without any protection
in the rate of resolution of biliary complications.
Non-stented patients had a signiﬁcantly higher
total number of PTC exchanges, but stent usage
was not associated with any diﬀerence in the risk-
adjusted odds of repetitive PTC exchanges.
An entire body of transplant literature is devo-
ted to biliary complications after liver trans-
plant, which remain common and ultimately aﬀect
clinical outcomes signiﬁcantly. In our population,
there was a high rate of biliary complications. This
likely has to do with our aggressive approach to
diagnosing these problems and concern about pre-
Fig. 4. Intra-operative biliary stenting
at orthotopic liver transplantation
(OLT) does not aﬀect cumulative
freedom from anastomotic biliary
complications. Biliary complications
were common in the study cohort, but
intra-operative biliary stenting was not
protective from the rate of freedom
from biliary therapy, as deﬁned by
continued need for an in-dwelling stent
in the bile duct or by the need for
continued invasive biliary procedures.
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vent long-term biliary morbidity. This analysis rep-
resents the actual clinical experience in a large
transplant program. An admitted limitation of the
analysis is a bias toward identifying a complication,
which may overestimate the complication rate,
which is diﬃcult to interpret retrospectively. Small
leaks identiﬁed during an early ERC may in fact
have been caused by high intraluminal pressure
during contrast injection during the study. The rate
of severe leaks among all patients with bile leaks
was 25%, and 10% of the study population had
more than 10 PTC exchanges. This rate likely
reﬂects local practice patterns at our institution in
the long-term management of patients with compli-
cated biliary pathology after transplant. After a
thorough review of the data, the high number of
PTC interrogations among non-stented patients is
likely related to the experience of a few patients
who had long-standing strictures that required
multiple PTC treatments, some for months and
years after transplant. These patients had complex
strictures, some with associated arterial insuﬃ-
ciency, and were not candidates for ERCP based
on recipient anatomy. These patients were essen-
tially PTC tube dependent, were undergoing repeti-
tive stent exchanges, and were not operative
candidates for biliary revision or retransplantation.
It is worth noting, however, that these few patients’
large number of procedures did not skew the multi-
variate model designed to predict the need for mul-
tiple PTC procedures. After adjusting for clinical
factors, stenting (or lack of stenting) was not asso-
ciated with a risk of undergoing multiple PTC pro-
cedures for an individual patient.
No other studies have attempted to ascribe a
stent-speciﬁc utilization rate for invasive biliary
interventions after liver transplant. The reported
complication rates after these procedures are low
(22–24), but multiple procedures are needed when
biliary complications are severe (15). In our cohort,
liver transplant recipients averaged four invasive
biliary procedures per patient, and we found signif-
icantly higher odds for ERC in stented patients,
and threefold higher rates of EGD during the ﬁrst
three months after transplant. The higher rate of
endoscopic interventions in the stented population
was likely related to the need for stent retrieval sec-
ondary to stent occlusion, increased intraluminal
debris, altered biliary chemistry, and reactive
inﬂammation that may contribute to strictures that
require multiple ERC treatments. Additionally,
secondary complications from having a stent in
place such as proximal stent migration, failure of
stent passage, and cholangitis could also be
responsible for the repetitive interventions. Severe
biliary complications in choledochocholedochosto-
my or anastomotic biliary complications in
patients with Roux-en-Y biliary–enteric drainage
usually require PTC procedures with frequent
exchanges. In our analysis, there was a trend
toward lower rates of multiple PTC exchanges in
the stented patients, but it is premature to state
that stents are protective from severe complica-
tions or major leaks that usually require PTC pro-
cedures. The need for chronic in-dwelling PTCs
with maintenance exchanges in this population is
likely multifactorial and could be related to biliary
complications in retransplant patients, the use of
split liver grafts, hepatic artery complications
aﬀecting biliary perfusion, and poor surgical candi-
dacy for operative biliary revision. With regard to
survival, the overall survival of the cohort at one,
three, and ﬁve yr is comparable to the rest of the
literature and national data as well (25). It is
Fig. 5. Post-orthotopic liver
transplantation (OLT) survival is
signiﬁcantly lower in patients with an
anastomotic biliary complication. After
liver transplant, anastomotic biliary
complications were associated with
signiﬁcantly higher mortality on
unadjusted and adjusted analyses.
Intra-operative biliary stenting did not
modify this association on multivariate
analysis.
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therefore not surprising that placing a stent at
transplant had no signiﬁcant eﬀect on mortality.
The signiﬁcant association between anastomotic
biliary complications and death was more impres-
sive, but death after liver transplant is often related
to multiple factors, proximity to the operative
event, accumulation of other organ dysfunction,
and the clinical penetrance of comorbidities in the
post-transplant course.
The independent eﬀect of biliary complications
on mortality was also notable, which has been
shown elsewhere (3, 21, 26), and importantly was
not modiﬁed by biliary stents. This was particu-
larly interesting, because the survival within the
ﬁrst post-transplant year was similar between those
with and without biliary complications. This may
be driven by an aggressive early approach to man-
aging these complications by our group, with sepa-
ration of the mortality curves over time due to a
cascade of morbidity from these complications,
including frequent hospitalization, chronic infec-
tion, debilitation, and attendant secondary compli-
cations.
While our study delineates the association
between intra-operative biliary stent usage and the
morbidity of multiple biliary interventions, there
are limitations to our analysis. This study repre-
sents the experience of a single transplant program
and the clinical biases therein. The choice to place
biliary stents was based on prior clinical percep-
tions that internal biliary stents may avoid anasto-
motic leaks and limit the need for additional
procedures. A clear era eﬀect on stent usage was
present as well, which we attempted to adjust for
in our models. As a retrospective study, the clinical
context and nuances related to medical decision-
making in the management of post-transplant
patients may be lost and therefore aﬀect our ﬁnd-
ings. We excluded patients with intrahepatic biliary
strictures, which we argue arise from an alternate
mechanism. This exclusion may have also removed
some patients who had anastomotic complications
as well, which therefore may have underrepre-
sented the biliary interventions needed speciﬁcally
for those speciﬁc complications. These are limita-
tions of many retrospective clinical studies, but this
analysis shows an increased risk for repetitive bili-
ary interventions in patients who were stented at
transplant in an experienced liver transplant pro-
gram.
The study clearly calls into question the utility of
biliary stents in the operating room (6). This study
and our experience have prompted us to eliminate
biliary stent utilization at transplant and delay use
of ERC early after transplant. Further study with
a randomized controlled trial could help elucidate
the true morbidity related to stents in subsets of
patients deemed to be at higher risk. However,
broader studies of surgical outcomes using granu-
lar multicenter clinical data may represent the best
approach to feed directly back into quality
improvement initiatives at transplant programs.
Until such studies are initiated, liver transplant
programs with an interest in complication manage-
ment and surgical quality improvement will con-
tinue to rely on retrospective single-center studies
from similar centers and analyses of their own
experiences.
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